Healthcare Regulatory Affairs Outsourcing Market Report 2026

The healthcare regulatory affairs outsourcing market size has grown strongly in recent years. It will grow from $7.01 billion in 2025 to $7.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing globalization of pharmaceutical supply chains, rising complexity of multi regional regulatory frameworks, growing outsourcing of non core pharmaceutical functions, expansion of clinical trial activity across emerging markets, increasing compliance requirements for drug safety and labeling standards.

The healthcare regulatory affairs outsourcing market size is expected to see strong growth in the next few years. It will grow to $10.64 billion by 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing adoption of ai enabled regulatory intelligence platforms, increasing complexity of biologics and personalized medicine approvals, expansion of real time regulatory monitoring systems, rising demand for faster drug approval timelines, increasing regulatory scrutiny for advanced therapies and combination products. Major trends in the forecast period include increasing adoption of cloud based regulatory information management systems, growing demand for cross border compliance harmonization services, expansion of pharmacovigilance outsourcing for post market surveillance, rising use of predictive analytics for regulatory risk assessment, increasing reliance on specialized regulatory consulting for complex biologics and gene therapies.

The increasing regulatory complexity across global healthcare markets is expected to propel the growth of the healthcare regulatory affairs outsourcing market going forward. Regulatory complexity in healthcare includes the expanding scope, variability, and increasing stringency of approval pathways, certification requirements, and compliance standards across multiple jurisdictions. This trend is driven by the implementation and transition toward more stringent regulatory frameworks, which are significantly elevating compliance obligations and approval thresholds. Healthcare regulatory affairs outsourcing is supporting this environment by enabling organizations to efficiently manage multi-region submissions, maintain robust compliance documentation, and align with evolving regulatory requirements through specialized expertise and regulatory intelligence capabilities. For instance, in December 2023, according to the European Commission, a Belgium-based government authority, under the in vitro diagnostic regulation, nearly 80% of in vitro diagnostic devices require notified body involvement compared to approximately 20% under the previous directive, highlighting a substantial increase in regulatory scrutiny and compliance burden. Therefore, the increasing regulatory complexity across global healthcare markets is contributing to and propelling the growth of the healthcare regulatory affairs outsourcing market.

Leading companies operating in the healthcare regulatory affairs outsourcing market are focusing on technology innovation, such as next-generation regulatory affairs platforms with integrated generative artificial intelligence, to automate workflows, enhance regulatory intelligence, and improve data consistency across global submissions. Next-generation regulatory affairs platforms are cloud-based systems that centralize regulatory information management, enable automated document processing, and incorporate cognitive computing capabilities to deliver advanced analytics and predictive insights. For example, in July 2024, ArisGlobal, a United States-based life sciences technology company, launched the LifeSphere Regulatory platform, a unified solution designed to support end-to-end regulatory affairs management. The platform integrates GenAI-enabled cognitive computing through the LifeSphere NavaX engine, offering enhanced regulatory analytics, automated content management, and integrated submission planning across global markets, thereby reducing manual effort and improving compliance quality.

In October 2024, ProductLife Group (PLG), a France-based regulatory affairs and compliance outsourcing company, acquired Callisto Regulatory Affairs Ltd for an undisclosed amount. Through this acquisition, ProductLife Group aimed to broaden its regulatory services portfolio and reinforce its presence across the United Kingdom and the European Union, while enhancing expertise in regulatory strategy, product registration, and compliance support for medicines and medical devices. Callisto Regulatory Affairs Ltd. is a UK-based company providing regulatory strategy, submissions, and compliance services for pharmaceutical, biotechnology, and medical device industries.

Major companies operating in the healthcare regulatory affairs outsourcing market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., ICON plc, Paraxel, Trident BioPharm Solutions, Freyr Solutions, APCER Life Sciences Inc., PrimeVigilance, ProClinical Consulting, Voisin Consulting Life Sciences, Regulatory Compliance Associates Inc. (RCA), Clinilabs Inc., Accell Clinical Research LLC, BioMapas, Continuum India, Alacrita, Regulatory Pharma Net srl, Elexes Regulatory Affairs Outsourcing, Qvigilance, RA Consultants Pvt Ltd, The FDA Group, Masuu Global, ProRelix Research, QxP Pharma Consultants, Pharma Wizard Consultancy.

North America was the largest region in the healthcare regulatory affairs outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the healthcare regulatory affairs outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the healthcare regulatory affairs outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The healthcare regulatory affairs outsourcing market includes revenues earned by entities through regulatory writing and publishing, clinical trial application support, product registration and submission management, and pharmacovigilance and safety reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.